EGFR and neoplasm: Moreover, low tumor mitotic activity was associated with better prognosis in LUAD subgroups with EGFR mutations or pan-negative (no oncogenic alteration in genes including KRAS, EGFR, BRAF, ERBB2, PIK3CA, ALK, and ROS1) but not in those with KRAS or BRAF mutations (Figure 3C–D, Figure 2—figure supplement 4H–I).